Preview

Safety and Risk of Pharmacotherapy

Advanced search

ON THE ISSUE OF SAFETY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

https://doi.org/10.30895/2312-7821-2018-6-3-123-129

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are liders in selling both in the Russian Federation and worldwide. The combination of  analgesic, anti-inflammatory and antipyretic effects make the drugs  of this group very popular in patients with various diseases. The  realization of NSAIDs in pharmacies occurs both by prescription and  over-the-counter, so the safety assessment of the use of this group  of drugs remains relevant. In the current practice, self-administration (responsible selfmedication) of drugs of the NSAID  group is an additional factor affecting the safety of their intake. According to the studies, about 40 % of patients taking  NSAIDs consider that NSAIDS are absolutely safe, and more than 30  % of those taking OTC NSAIDs use them in excess of the  recommended dosages. We analyzed 3963 individual case safety  reports (ICSR) in the federal database «Pharmacovigilance» from  07.12.2008 to 31.08.2017. The inclusion criterions was the presence of information on the off-label application of NSAIDs in the ICSR,  reports of adverse effects that may be associated with the use of this drug or erroneous reports on the active substance, which was  not present in this drug. The most frequent mistakes in the  application were an increase of the daily dose, a change in the  method of administration to patient who are contraindicated with this drug. There were 9 ICSR of burning sensation in the anus with the  introduction of ibuprofen suppositories (not in the label), and 7 ICSR  of ineffectiveness of the active substance, which was not present in this drug.

About the Authors

N. Yu. Velts
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation

8/2 Petrovsky Blvd, Moscow 127051, Russian Federation

Senior Analyst of Department of Expert Analysis Methodology of the DEMPS. PhD



T. M. Bukatina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation

8/2 Petrovsky Blvd, Moscow 127051, Russian Federation

Senior Analyst of Department of Expert Analysis Methodology of the DEMPS. PhD



E. O. Zhuravleva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation

8/2 Petrovsky Blvd, Moscow 127051, Russian Federation

Head of Department for Expert Analysis of Medicinal Products’ Safety of the DEMPS



G. V. Kutekhova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation

8/2 Petrovsky Blvd, Moscow 127051, Russian Federation

Analyst of the 1st category of Department for Expert Analysis  of Medicinal Products’ Safety of the DEMPS



M. A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation

8/2 Petrovsky Blvd, Moscow 127051, Russian Federation

Senior Analyst Department for Evaluation of MIBPs Side Effects of the DEMPS



Yu. V. Olefir
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation

8/2 Petrovsky Blvd, Moscow 127051, Russian Federation

General Director. MD, Senior Research Associate



B. K. Romanov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation

8/2 Petrovsky Blvd, Moscow 127051, Russian Federation

Deputy General Director for Science Research. MD, Assistant Professor



S. V. Glagolev
Federal Service for Surveillance in Healthcare (Roszdravnadzor)
Russian Federation

4/1 Slavjanskaja square, Moscow 109074, Russian Federation

Deputy Head of Department — Chief of Department of Pharmacovigilance. PhD



V. A. Polivanov
Federal State Dudgetary Institution «Information and Methodological Centre for Expert Evaluation, Recording and Analysis of Circulation of Medicinal Products» of Roszdravnadzor
Russian Federation

4/1 Slavjanskaja square, Moscow 109074, Russian Federation

Director of the Centre for Monitoring Effective, Safe and  Rational use of Medicinal Products



References

1. Амелин АВ, Волчков ВА, Дмитриев ВА и др. Клиническая фармакология нестероидных противовоспалительных средств / под ред. Игнатова ЮД, Кукеса ВГ, Мазурова ВИ. М.: ГЭОТАР Медиа; 2010. [Amelin AV, Volchkov VA, Dmitriev VA, et al. Clinical pharmacology of non-steroidal anti-inflammatory drugs / Ed. Ignatova YD, Kukes VG, Mazurov VI. Moscow: GEOTAR Media; 2010 (In Russ.)]

2. Фармакология / под ред. Аляутдина РН. М.: ГЭОТАР Медиа; 2004. [Pharmacology / ed. Alautdin RN. Moscow: GEOTAR Media; 2004 (In Russ.)]

3. Енгалычева ГН, Сюбаев РД, Горячев ДВ. Исследования фармакологической безопасности лекарственных средств: экспертная оценка полученных результатов. Ведомости Научного центра экспертизы средств медицинского применения. 2017;7(2):92–7. [Engalycheva GN, Syubaev RD, Goryachev DV. Studies of pharmacological safety of medicines: expert evaluation of the results. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2017;7(2):92–7 (In Russ.)]

4. Каратеев АЕ. Ошибки и проблемы при использовании нестероидных противовоспалительных препаратов. РМЖ. 2008;10:650. [Karateev AE. Errors and problems with the use of non-steroidal anti-inflammatory drugs. RMZh = RMJ. 2008;10:650 (In Russ.)]

5. Wilcox C, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the- counter pain relievers: focus on non-steroidal anti-inflammatory drugs. J Rheumatol. 2005;32(11):2218–24.

6. Вельц НЮ, Журавлева ЕО, Букатина ТМ, Кутехова ГВ. Нестероидные противовоспалительные препараты: проблемы безопасности применения. Безопасность и риск фармакотерапии. 2018;6(1):11–8. DOI: 10.30895/2312-7821-2018-6- 1-11-18. [Velts NYu, Zhuravleva EO, Bukatina TM, Kutekhova GV. Nonsteroidal anti- inflammatory drugs: problems of safe use. Bezopasnost i risk farmakoterapii = Safety and Risk of Pharmacotherapy. 2018;6(1):11–8. DOI: 10.30895/2312-7821-2018-6-1-11-18 (In Russ.)]

7. Журавлева ЕО, Вельц НЮ, Затолочина КЭ, Дармостукова МА, Лепахин ВК, Романов БК и др. Анализ спонтанных сообщений о нежелательных реакциях, развившихся при применении лекарственных средств во время беременности. Безопасность и риск фармакотерапии. 2017;(2):61–9. [Zhuravleva EO, Velts NYu, Zatolochina KE, Darmostukova MA, Lepakhin VK, Romanov BC, et al. Analysis of spontaneous reports of adverse reactions that develop with the use of drugs during pregnancy. Bezopasnost i risk farmakoterapii = Safety and risk of pharmacotherapy. 2017;(2):61–9 (In Russ.)]

8. Красных ЛМ, Смирнов ВВ, Василенко ГФ, Горошко ОА, Егоренков ЕА, Зозина ВИ. Различия в фармакокинетике ибупрофена в моно- и многокомпонентных препаратах. Ведомости научного центра экспертизы средств медицинского применения. 2017;7(2):117–21. [Krasnykh LM, Smirnov VV, Vasilenko GF, Goroshko OA, Egorenkov EA, Zozina VI. Differences in the pharmacokinetics of ibuprofen in mono- and multi-component drugs. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2017;7(2):117– 21 (In Russ.)]

9. Бурова ЕД, Ходько СВ, Гущина СВ, Макарова МН, Макаров ВГ. Управление рисками для обеспечения качества доклинических исследований лекарственных средств. Ведомости научного центра экспертизы средств медицинского применения. 2017;7(1):25–2. [Burova ED, Khodko SV, Gushchina SV, Makarova MN, Makarov VG. Riskmanagement to ensure the quality of preclinical studies of drugs. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2017;7(1):25–2 (In Russ.)]

10. Schrör K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs. 2007;9(3):195–204.

11. Меркулов ВА, Бунятян НД, Сакаева ИВ, Рычихина ЕМ, Лепахин ВК, Романов БК и др. Совершенствование системы оценки информации о безопасности лекарственных средств при проведении клинических исследований. Ведомости Научного центра экспертизы средств медицинского применения. 2014;(1):20–6. [Merkulov VA, Bunyatyan ND, Sakaeva IV, Richihina EM, Lepakhin VK, Romanov BK, et al. Improving the system of evaluating information on the safety of medicines in clinical trials. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2014;(1):20–6 (In Russ.)]

12. Енгалычева ГН, Сюбаев РД, Тиханова АЛ, Васильев АН. Экспертные критерии доклинической оценки безопасности лекарственной терапии у пациентов педиатрической популяции. Ведомости Научного центра экспертизы средств медицинского применения. 2013;(3):12–8. [Engalycheva GN, Syubaev RD, Tikhanova AL, Vasilyev AN. Expert criteria for preclinical evaluation of drug therapy safety in pediatric patients. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2013; (3):12–8 (In Russ.)]

13. Аляутдин РН, Романов БК, Гусейнов МД, Лопатин ПВ, Зилфикаров И. Экспериментальная скрининговая оценка стресспротекторного действия фитопрепаратов. РМЖ. 2008;3:29-33. [Alyautdin RN, Romanov BK, Huseynov MD, Lopatin PV, Zilfikarov I. Experimental screening evaluation of the stress-protection action of herbal remedies. RMZh = RMJ. 2008;3:29–33 (In Russ.)]

14. Журавлева МВ, Обжерина АЮ. Актуальные вопросы повышения безопасности применения нестероидных противовоспалительных препаратов: значение клинической фармакологии. Ведомости Научного центра экспертизы средств медицинского применения. 2011;(2):31–4. [Zhuravleva MV, Obzherina AYu. Topical issues of improving the safety of non-steroidal anti-inflammatory drugs: the importance of clinical pharmacology. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2011;(2):31–4 (In Russ.)]


Review

For citations:


Velts N.Yu., Bukatina T.M., Zhuravleva E.O., Kutekhova G.V., Darmostukova M.A., Olefir Yu.V., Romanov B.K., Glagolev S.V., Polivanov V.A. ON THE ISSUE OF SAFETY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS. Safety and Risk of Pharmacotherapy. 2018;6(3):123-129. (In Russ.) https://doi.org/10.30895/2312-7821-2018-6-3-123-129

Views: 2029


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2312-7821 (Print)
ISSN 2619-1164 (Online)